Our team is working to develop novel antiviral compounds to treat Coronavirus and Influenza Virus infections by leveraging our proprietary drug discovery platform.

We are diligently working to leverage our core competencies and decade of experience in the antiviral therapeutics space to combat the global health crisis of COVID-19. Our COVID-19 program consists of work performed globally by contract research organizations and in our own laboratory. Given the growing global need for a treatment, our focus is to advance this program further into preclinical development as quickly and efficiently as possible. Additionally, we are working to advance preclinical candidates under development for the treatment of influenza infection.

Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including hepatitis C, influenza, norovirus and coronaviruses.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including hepatitis C, influenza, norovirus and coronaviruses.

Learn More
Program Discovery Preclinical Phase 1 Phase 2a Phase 3
Hepatitis C CC-31244 - University of MD
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase in progress
Phase 3 Phase not started
Influenza CC-42344
(Influenza A PB2 Inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Influenza Influenza A/B Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Coronavirus (COVID-19) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Norovirus (Gastroenteritis) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation View Fact Sheet

Corporate Overview

Gary Wilcox, Ph.D., Chairman and CEO provides background on the Company's innovative platform and highlights upcoming program milestones.